These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 32158625)

  • 1. A
    Xu F; Lin H; He P; He L; Chen J; Lin L; Chen Y
    Oncoimmunology; 2020; 9(1):1731943. PubMed ID: 32158625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
    Xu F; Zhang H; Chen J; Lin L; Chen Y
    Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
    Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
    Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analyses of a CD8
    Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
    BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.
    Fan T; Lu Z; Liu Y; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Front Immunol; 2021; 12():665407. PubMed ID: 34177903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
    Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
    Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
    Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
    Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
    Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
    Front Immunol; 2020; 11():590618. PubMed ID: 33391264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification and prognosis prediction based on inflammation-related gene signature in lung squamous carcinoma.
    Zhai W; Chen S; Duan F; Wang J; Zhao Z; Lin Y; Rao B; Wang Y; Zheng L; Long H
    Cancer Med; 2023 Feb; 12(4):4968-4980. PubMed ID: 36056909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma.
    Zhou W; Zhang W
    BMC Cancer; 2022 Jun; 22(1):694. PubMed ID: 35739504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients.
    Liu X; Zhao D; Shan Y; Cui W; Xie Q; Jiang J; Peng W; Zhang C; Duan C
    Sci Rep; 2022 Dec; 12(1):20737. PubMed ID: 36456645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
    Shi C; Liu S; Tian X; Wang X; Gao P
    BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
    Fu J; Li Y; Li C; Tong Y; Li M; Cang S
    Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
    Wang X; Huang Z; Li L; Wang G; Dong L; Li Q; Yuan J; Li Y
    BMC Cancer; 2022 Aug; 22(1):866. PubMed ID: 35941578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer.
    Zhang F; Zhong W; Li H; Huang K; Yu M; Liu Y
    Front Cell Dev Biol; 2021; 9():665265. PubMed ID: 34124046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma.
    Miao TW; Yang DQ; Chen FY; Zhu Q; Chen X
    Biosci Rep; 2022 Aug; 42(8):. PubMed ID: 35866375
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Zhao L; Qu X; Wu Z; Li Y; Zhang X; Guo W
    Aging (Albany NY); 2020 Jul; 12(14):14556-14568. PubMed ID: 32694238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.